Occult Nodal Involvement in Sinonasal Squamous Cell Carcinoma
American Journal of Rhinology & Allergy · 2026
DOI: 10.1177/19458924251371257 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Rhinology & Allergy, 2026. Verfasst von Samer T Elsamna und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head & Neck Surgery, University of South Florida Morsani College of Medicine, Tampa, Florida. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, Paranasal Sinus Neoplasms, Lymph Nodes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Abstract (Originalsprache)
Background
Sinonasal squamous cell carcinoma (SNSCC) is an aggressive subtype of sinonasal cancer. While elective neck dissection (END) is not typically recommended for SNSCC, occult nodal involvement (ONI) may be present. We therefore sought to evaluate the incidence, associated factors, and survival impact of ONI in SNSCC.
Methods
The National Cancer Database was queried for patients with SNSCC from 2004 to 2016. Data regarding patient demographics, clinicopathology, and treatment were obtained. Univariate and multivariate logistic regression and Kaplan–Meier analyses were conducted to identify predictors of ONI with odds ratios (ORs) and overall survival.
Results
In total, 522 patients satisfied inclusion criteria. Most patients were elderly (>60 years old, 55.0%), male (67.2%), White (86.4%), and insured with Medicare (44.1%). Cases of SNSCC most frequently involved the paranasal sinuses (69.7%), were T-stage 4 (50.6%), moderately differentiated (52.5%), underwent treatment at academic centers (76.4%), and lacked lymphovascular invasion (LVI, 84.4%). ONI was observed in 10.9% of patients. Following propensity score matching, ONI significantly negatively impacted survival: 3 year survival was 65% for patients without ONI and 35% for patients with ONI (log-rank P < .001). The highest rate of ONI was observed in patients with LVI (31.4%). On multivariate analysis, LVI was the sole predictor of ONI (OR: 6.75, 95% confidence interval: 3.09-14.73, P < .001).
Conclusions
ONI was identified in 10.9% of patients with SNSCC and was found to be a negative prognostic factor for survival. Patients with identified LVI may benefit from END. Level of Evidence: 4
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otolaryngology-Head & Neck Surgery, University of South Florida Morsani College of Medicine, Tampa, Florida.
- Department of Otolaryngology-Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey.
- Department of Otolaryngology-Head and Neck Surgery, Albert Einstein School of Medicine/Montefiore Medical Center, Bronx, New York.
- Center for Skull Base and Pituitary Surgery, Neurological Institute of New Jersey, Rutgers New Jersey Medical School, Newark, New Jersey.
- Department of Neurological Surgery, Rutgers New Jersey Medical School, Newark, New Jersey.
- Department of Ophthalmology and Visual Science, Rutgers New Jersey Medical School, Newark, New Jersey.
ORCID-Profile: Aman M Patel, Lucy Revercomb, Christina H Fang, Jean Anderson Eloy
Zitieren
APA
Elsamna, S. T., Patel, A. M., Shaikh, I., Revercomb, L., Shah, V. P., Patel, P., Fang, C. H., Baredes, S., & Eloy, J. A. (2026). Occult Nodal Involvement in Sinonasal Squamous Cell Carcinoma. American Journal of Rhinology & Allergy. https://doi.org/10.1177/19458924251371257
Vancouver
Elsamna ST, Patel AM, Shaikh I, Revercomb L, Shah VP, Patel P, et al. Occult Nodal Involvement in Sinonasal Squamous Cell Carcinoma. American Journal of Rhinology & Allergy. 2026. doi:10.1177/19458924251371257
BibTeX
@article{Elsamna2026,
author = {Elsamna, Samer T and Patel, Aman M and Shaikh, Ibraheem and Revercomb, Lucy and Shah, Vraj P and Patel, Prayag and Fang, Christina H and Baredes, Soly and Eloy, Jean Anderson},
title = {Occult Nodal Involvement in Sinonasal Squamous Cell Carcinoma},
journal = {American Journal of Rhinology & Allergy},
year = {2026},
doi = {10.1177/19458924251371257}
}
EUVIMED